帕金森病中的溴隐亭
Bromocriptine in Parkinsonism.
作者信息
Calne D B, Teychenne P F, Claveria L E, Eastman R, Greenacre J K, Petrie A
出版信息
Br Med J. 1974 Nov 23;4(5942):442-4. doi: 10.1136/bmj.4.5942.442.
Abstract
Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa. Neurological deficits improved by almost 20% in severely disabled patients; amelioration of mildly affected patients was about 10%. Adverse reactions were similar to those encountered with levodopa-they were all dose-dependent and reversible. These observations are discussed in relation to certain theoretical advantages which might be expected from a drug which acts directly on dopaminergic receptors.
摘要
溴隐亭是一种直接作用于多巴胺能受体的药物，在一项针对20名已接受包括左旋多巴在内的常规治疗的特发性帕金森病患者的双盲研究中，发现它具有显著的治疗作用。在严重残疾患者中，神经功能缺损改善了近20%；轻度受影响患者的改善约为10%。不良反应与左旋多巴相似——它们均与剂量相关且可逆。结合一种直接作用于多巴胺能受体的药物可能具有的某些理论优势对这些观察结果进行了讨论。
相似文献
1
Bromocriptine in Parkinsonism.帕金森病中的溴隐亭
Br Med J. 1974 Nov 23;4(5942):442-4. doi: 10.1136/bmj.4.5942.442.
2
Idiopathic parkinsonism treated with bromocriptine.用溴隐亭治疗特发性帕金森病。
Lancet. 1975 Sep 13;2(7933):473-6. doi: 10.1016/s0140-6736(75)90546-2.
3
Comparison between lergotrile and bromocriptine in parkinsonism.培高利特与溴隐亭治疗帕金森病的比较。
Ann Neurol. 1978 Apr;3(4):319-24. doi: 10.1002/ana.410030408.
4
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.多巴胺激动剂——麦角衍生物：溴隐亭：帕金森病的治疗
Mov Disord. 2002;17 Suppl 4:S53-67. doi: 10.1002/mds.5562.
5
Dopaminephilic properties of ergot alkaloids.麦角生物碱的嗜多巴胺特性。
Fed Proc. 1978 Jun;37(8):2202-6.
6
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.溴隐亭治疗帕金森病：长期治疗、剂量反应及与左旋多巴的比较。
J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1101-8. doi: 10.1136/jnnp.39.11.1101.
7
Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.两种多巴胺能麦角衍生物——溴隐亭和麦角腈之间的交叉耐受性。
Br J Clin Pharmacol. 1980 Jan;9(1):47-50. doi: 10.1111/j.1365-2125.1980.tb04795.x.
8
Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.脑多巴胺受体刺激与帕金森病症状缓解：溴隐亭与左旋多巴之间的关系。
Ann Neurol. 1978 Sep;4(3):263-7. doi: 10.1002/ana.410040313.
9
Current status of dopamine agonists in Parkinson's disease management.多巴胺激动剂在帕金森病治疗中的现状
Drugs. 1993 Sep;46(3):384-393. doi: 10.2165/00003495-199346030-00005.
10
Action of L- -methyldopa-hydrazine on the blood pressure of patients receiving levodopa.L-甲基多巴肼对接受左旋多巴治疗患者血压的作用
Br J Pharmacol. 1972 Jan;44(1):162-4. doi: 10.1111/j.1476-5381.1972.tb07249.x.
引用本文的文献
1
Multidisciplinary inpatient care for Parkinson's disease: a single-centre cohort study on improvements in gait, overall motor function, and quality of life.帕金森病的多学科住院治疗：一项关于步态、整体运动功能和生活质量改善的单中心队列研究。
Neurol Res Pract. 2025 Sep 2;7(1):62. doi: 10.1186/s42466-025-00422-y.
2
Defining Parkinson's Disease: Past and Future.定义帕金森病：过去与未来。
J Parkinsons Dis. 2024;14(s2):S257-S271. doi: 10.3233/JPD-230411.
3
Role of dopamine agonists in Parkinson's disease therapy.多巴胺激动剂在帕金森病治疗中的作用。
J Neural Transm (Vienna). 2023 Jun;130(6):863-873. doi: 10.1007/s00702-023-02647-0. Epub 2023 May 11.
4
Parkinson's disease, dopaminergic drugs and the plant world.帕金森病、多巴胺能药物与植物界
Front Pharmacol. 2022 Sep 5;13:970714. doi: 10.3389/fphar.2022.970714. eCollection 2022.
5
Identification of ER/SR resident proteins as biomarkers for ER/SR calcium depletion in skeletal muscle cells.鉴定内质网/肌浆网驻留蛋白作为骨骼肌细胞内质网/肌浆网钙耗竭的生物标志物。
Orphanet J Rare Dis. 2022 Jun 13;17(1):225. doi: 10.1186/s13023-022-02368-9.
6
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.一种无靶点筛选方法鉴定出可稳定内质网驻留蛋白质组的已批准药物。
Cell Rep. 2021 Apr 27;35(4):109040. doi: 10.1016/j.celrep.2021.109040.
7
Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review.帕金森病处方模式与决定因素：一项系统文献综述
Parkinsons Dis. 2019 Nov 3;2019:9237181. doi: 10.1155/2019/9237181. eCollection 2019.
8
Classical dopamine agonists.经典多巴胺激动剂。
J Neural Transm (Vienna). 2019 Apr;126(4):449-454. doi: 10.1007/s00702-019-01989-y. Epub 2019 Feb 25.
9
Milestones of Parkinson's Disease Research: 200 Years of History and Beyond.帕金森病研究的里程碑：200年的历史及未来
Neurosci Bull. 2017 Oct;33(5):598-602. doi: 10.1007/s12264-017-0178-2. Epub 2017 Sep 11.
10
L-DOPA.左旋多巴
J Parkinsons Dis. 2017;7(s1):S3-S10. doi: 10.3233/JPD-179004.
本文引用的文献
1
Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.帕金森病：不同脑区中左旋多巴脱羧酶的活性
Science. 1970 Dec 11;170(3963):1212-3. doi: 10.1126/science.170.3963.1212.
2
Similarities between neurologic effects of L-dopa and of apomorphine.左旋多巴与阿扑吗啡对神经系统作用的相似性。
N Engl J Med. 1970 Jan 1;282(1):31-3. doi: 10.1056/NEJM197001012820107.
3
Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".大鼠脑尾状核中对多巴胺敏感的腺苷酸环化酶及其与“多巴胺受体”的相似性。
Proc Natl Acad Sci U S A. 1972 Aug;69(8):2145-9. doi: 10.1073/pnas.69.8.2145.
4
Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.麦角药物对中枢儿茶酚胺能神经元的作用：刺激中枢多巴胺能神经元的证据。
J Pharm Pharmacol. 1973 May;25(5):409-12. doi: 10.1111/j.2042-7158.1973.tb10037.x.
Zotero 插件